TBC1D3, a hominoid oncoprotein, is encoded by a cluster of paralogues located on chromosome 17q12  by Hodzic, Didier et al.
6) 731–736
www.elsevier.com/locate/ygenoGenomics 88 (200TBC1D3, a hominoid oncoprotein, is encoded by a cluster of paralogues
located on chromosome 17q12
Didier Hodzic 1, Chen Kong 1, Marisa J. Wainszelbaum, Audra J. Charron,
Xiong Su, Philip D. Stahl ⁎
Department of Cell Biology and Physiology, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO 63110, USA
Received 24 April 2006; accepted 25 May 2006
Available online 24 July 2006Abstract
TBC1D3 is a member of the TBC1 domain family of proteins that stimulates the intrinsic GTPase activity of RAB5A, an essential actor in
early endosome trafficking. Oncogenic properties of TBC1D3 have been demonstrated previously both in vitro and in mouse models. Although
the oncogenic mechanism of TBC1D3 has yet to be elucidated, the TBC1D3 locus (chromosome 17q12) is amplified in 15% of primary prostate
tumors. Here, we describe eight highly related TBC1D3 paralogues located within that genomic region, potentially encoding six variant TBC1D3
proteins. We found that human tissues display specific transcription patterns of these paralogues. Furthermore, that pattern was altered in several
primary prostate tumors in comparison to healthy prostate tissues. Potential TBC1D3 oncogenic mechanisms are discussed in light of these results.
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regulation of intracellular vesicular trafficking [1]. RABs and
their specific effector proteins are involved in the spatial and
temporal regulation of membrane fusion events throughout the
cell. The complexity of this process is reflected by the presence
of at least 60 unique RAB proteins encoded within the human
genome [2]. The cycling of a small GTPase between its GTP-
bound and its GDP-bound state is essential for its action and is
tightly regulated by the interplay of its effectors, the GTPase
activating proteins (GAPs) and the guanine nucleotide
exchange factors [3]. RAB GAPs are characterized by the
presence of a TBC (Tre-2/Bub2/Cdc16) domain [4] that consists
of a stretch of 200 amino acids that catalyzes the GTPase
activity. TBC1D3 (also called PRC17, for prostate cancer gene,
chromosome 17, MIM *607741) protein includes a TBC
domain and has been reported to possess GAP activity toward
RAB5A [5], which plays an essential role in early endosome
fusion. At the amino acid level, the 549-amino-acid TBC1D3
protein shares 81 and 35% identity with the N-terminal 499⁎ Corresponding author. Fax: +1 314 362 1490.
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doi:10.1016/j.ygeno.2006.05.009amino acids of TRE2 (approved gene symbol USP6) and the N-
terminal 358 amino acids of RNTRE (approved gene symbol
USP6NL), respectively. TRE2 is an oncogene [6] that arose
from a recent chimeric fusion of the TBC1D3 and USP32 genes
[7], and RNTRE is a GAP for RAB5A and RAB41 [8–10].
Interestingly, while RNTRE is an ancient gene, TRE2 is a
hominoid-specific gene [7] and TBC1D3 orthologues are
conspicuously absent from the mouse genome.
In vitro studies and analyses of human tumor tissues
demonstrated that TBC1D3 is an oncogene. Transfection of
NIH3T3 cells with TBC1D3 (or a specific transcript of TRE2
that shows a high degree of identity with TBC1D3) elicits focus
formation in soft agar. These transformed cells are tumorigenic
in nude mice [5,6]. Furthermore, the TBC1D3-encoding region,
located on chromosome 17q12, is amplified in 15% of primary
prostate tumors and in more than half of metastatic prostate
tumors [5].
The clear link between TBC1D3 expression and cellular
transformation underscores the importance of a better under-
standing of the physiological function of TBC1D3. After
examining the human genome, we found that the TBC1D3 gene
has undergone several duplications that result in the existence of
eight gene copies (paralogues) clustered on chromosome
732 D. Hodzic et al. / Genomics 88 (2006) 731–73617q12. Using restriction length polymorphisms, we found that
TBC1D3 mRNAs are transcribed from different paralogues.
Specific expression patterns of these paralogues were restricted
to specific human tissues and modified in several prostate
tumors.
Results
Eight TBC1D3 paralogues are located on chromosome 17q12
The human genome (build 35.1) was interrogated with the
human TBC1D3 cDNA sequence (GenBank Accession No.
NM_032258.1) using BLAST [11]. Surprisingly, no fewer thanFig. 1. TBC1D3 is transcribed from up to eight paralogues clustered on chromosome
located on chromosome 17q12. The official TBC1D3 nomenclature (reviewed during
combinations of TBC1D3 missense changes are shown for each paralogue and the po
genes that are expressed in different human tissues and prostate tumors are indicate
relative to the TBC domain and of the cDNA fragments used in RFLP experimen
“TBC1D3 library” is depicted with the polymorphic NdeI site in bold. The DdeI rest
depicted with the polymorphic DdeI site in bold. (C) NdeI and DdeI digestion of the
library, respectively. (D) Sequencing of the codon corresponding to the polymorphic11 distinct genomic loci, all located on chromosome 17,
matched the input sequence with various degrees of homology.
Specifically, the exonic sequences of the eight putative copies of
the TBC1D3 gene displayed 97 to 100% identity with the input
sequence. These paralogues are physically clustered in two
groups of four genes (annotated A to H, Fig. 1A). Each cluster
spans ∼400 kb located between coordinates 31,500K and
31,900K (paralogues A–D) and 33,300K and 33,700K (para-
logues E–H) of chromosome 17. HGCN and Ensembl
references for each paralogue, when available, are listed in
Table 1. (The official HGCN annotation of TBC1D3 paralogues
has just been reviewed.) Two additional copies of TBC1D3-like
sequences (55,440K–55,450K and 57,696K–57,707K) also17q12. (A) Depiction of two groups of four TBC1D3 paralogues (boxes A–H)
manuscript submission) adopted for paralogues A to H is shown in Table 1. The
sition of each variable amino acid is indicated in subscript. The combinations of
d. (B) Positions of amino acid variations encoded by the TBC1D3 paralogues
ts. The NdeI restriction map of the 1074-bp ApaI fragment purified from the
riction map of the 420-bp PCR fragment amplified from the TBC1D3 library is
purified ApaI fragment and the 420-bp PCR fragment derived from the TBC1D3
amino acid position 354 of the ApaI fragment purified from the TBC1D3 library.
Table 1
HGCN (HUGO Gene Nomenclature Committee) and Ensembl annotations of
eight TBC1D3 paralogues on 17q12
Paralogue HGCN designation Ensembl designation
31,500K–31,900K
A TBC1D3B –
B TBC1D3C ENSG00000188849
C TBC1D3H –
D TBC1D3G ENSG00000161583
33,300K–33,700K
E TBC1D3F ENSG00000185128
F TBC1D3E ENSG00000197681
G TBC1D3D ENSG00000174115
H TBC1D3 ENSG00000186914
733D. Hodzic et al. / Genomics 88 (2006) 731–736map to chromosome 17 but display lower homologies and were
not further considered in this study. In addition to the TBC1D3-
like sequences, the 5′ portion of ubiquitin-specific protease 6
gene (USP6 or TRE2) also showed a significant homology
(81% identity at the amino acid level). USP6 is located on the
short arm of chromosome 17 (4970K–5020K) and results from
the fusion of TBC1D3 and USP32 [7].
The alignment of the predicted protein sequences encoded
by paralogues A to H revealed the presence of six missense
changes (Figs. 1A and 1B). Five of the six changes are
located in the TBC domain. These variants were used to
search human expressed sequence tag (EST) databases; the
results (not shown) indicate that potentially all TBC1D3
paralogues are expressed in various human tissues. Since gene
pairs C/D and E/F each display the same set of missense
changes (Fig. 1A), the TBC1D3-related proteins are predicted
to exist as six different isoforms. Using Ensembl, the human
17q12 syntenic region in chimpanzee was examined and
revealed the existence of a similar cluster of TBC1D3
paralogues. In contrast, no sequence related to the human
TBC1D3 gene could be found in the mouse genome, the
closest homology (35% at the amino acid level) being with
the N-terminal 358 amino acids of murine Usp6nl.
A variable number of TBC1D3 paralogues are actively
transcribed in human tissues
Placental RNA
Two of the missense changes (I117/T117 and I157/M157, see
Fig. 1B) resulted in DdeI and NdeI restriction fragment length
polymorphisms (RFLPs), respectively (Fig. 1B). These RFLPs
were used to determine which TBC1D3 paralogues are actively
transcribed. The full-length TBC1D3 cDNA was amplified by
RT-PCR from human placenta total RNA. The PCR product
was cloned and transformed in TOP 10 cells. Plasmid DNA
from the entire transformation was isolated and is further
referred as to the “TBC1D3 library.”
A 1074-bp ApaI fragment including all missense changes
(Fig. 1B) was purified from the TBC1D3 library. To examine
the I157/M157 polymorphism, that fragment was further digested
with NdeI. As shown in Fig. 1C, the NdeI restriction pattern
generated only two fragments with the predicted sizes of 206and 868 bp. The absence of the 144- and 62-bp NdeI restriction
fragments indicates that the polymorphic NdeI restriction site is
not present in the ApaI fragment (see schematic in Fig. 1B).
Hence, in human placenta, one or several I157-encoding genes
(E–H) are actively transcribed, while M157-encoding genes (A–
D) are not.
To examine the I117/T117 RFLP (Fig. 1A), an amplicon
derived from the TBC1D3 library was amplified with primers
Pf1 and Pr420 (Fig. 1B). The DdeI restriction pattern of the
420-bp amplicon consisted of four fragments whose predicted
sizes were compatible with the presence of a DdeI polymorph-
ism (Fig. 1C). To confirm that the 309-bp (243 bp + 66 bp)
fragment did not originate from a partial DdeI digestion, it was
purified and sequenced; the triplet encoding position 117
exclusively encoded an isoleucine (not shown). We therefore
concluded that both I117 and T117 isoforms are expressed in
placenta, the latter originating from gene H (Fig. 1A).
Codon 354 (K/Q354), which does not generate an RFLP, was
examined by sequence analysis of the ApaI fragment isolated
from the TBC1D3 library. An SNP that corresponds to the
expression of both K and Q at position 354 (Fig. 1D) was
clearly detected. However, in agreement with the finding that
genes A–D are not expressed, sequencing of the ApaI fragment
revealed that codons 149, 201, and 248 exclusively encoded
valine, leucine, and proline residues, respectively (data not
shown).
The combined results obtained from RFLP and SNP analyses
indicate that, in placenta, at the very least, two TBC1D3
paralogues (E/F and H) are actively transcribed from the second
cluster of four genes located between 33,300K and 33,700K,
while none of the genes from the other cluster (31,500K–
31,800K) are actively transcribed.
Expression in other human tissues
Primers Pf200 and Pr540 (Fig. 2A) were used in semi-
quantitative PCRs using cDNA from various human tissues
(Multiple Tissue cDNAs; BD Biosciences). These results (not
shown) indicated that the TBC1D3 expression level was
comparable among all tissues examined (from 6 to 10 in
arbitrary units), except for skeletal muscle, where its expression
level was significantly lower (1 in arbitrary units). It is
important to mention that the overall level of TBC1D3
expression was modest. Indeed, TBC1D3 PCR product could
not be detected after 25 amplification cycles of 5 ng of cDNA
from any human tissue sample and 40 cycles of amplification
were necessary to detect the TBC1D3 amplicon after SYBR
green staining of the agarose gel.
It was of great interest to determine the qualitative pattern of
TBC1D3 paralogue expression in normal human tissues to
compare this pattern with cancerous tissues. Pf200 and Pr540
were designed to amplify a 340-bp fragment that contains both
the DdeI and the NdeI polymorphic sites (Figs. 2A and 2B) and
that distinguishes between paralogues. RFLP analyses were
then carried out for each human tissue. Following DdeI
digestion (Fig. 2A), the intensity of the 216- and 150-bp
fragments, which originate from the I117 and T117 isoforms,
respectively, was quantified (Alphaease FC) to estimate the I117/
Fig. 2. Relative expression of TBC1D3 I/T117 and I/M157 isoforms in human tissues. A 340-bp TBC1D3 PCR fragment was amplified (40 cycles) from various human
tissue cDNAs (lanes 1, spleen; 2, thymus; 3, prostate; and 4, testis) with primers pF200 and pR540 and digested with either (A) DdeI or (B) NdeI. DdeI and NdeI
restriction maps of the 340-bp fragment are depicted with the polymorphic sites in bold. (C) Relative expression of TBC1D3 I117/T117 and I157/M157 isoforms in human
tissues. Black bars: ratio of the measured intensities of the 216-bp to the 150-bp fragment (I117/T117) generated by the DdeI digestion. Gray bars: ratio of the measured
intensities of the 265-bp to the 327-bp fragment (M157/I157) generated by the NdeI digestion. For each human tissue, the number in parentheses refers to the number of
individual samples in each pool of tissue cDNA. (D) Relative expression levels of TBC1D3 I/T117 and I/M157 isoforms in human prostate tumors. Black bars: ratio of
the measured intensities of the 216-bp to the 150-bp fragment (I117/T117) generated by the DdeI digestion. Gray bars: ratio of the measured intensities of the 265-bp to
the 327-bp fragment (M157/I157) generated by the NdeI digestion.
734 D. Hodzic et al. / Genomics 88 (2006) 731–736T117 ratio for each tissue examined. This ratio varied from 0 in
the heart, where the T117 paralogue (gene H) was the sole
detectable transcription product, to 0.45 in testis (Figs. 2A and
2C).
The NdeI polymorphism displayed a much more restrictive
tissue distribution; indeed, the M157 isoform was specifically
detected in pancreas, thymus, and testis (Figs. 2B and 2C). The
quantification of the 265- and 327-bp digestion productsindicated that the M157/I157 ratio ranged between 0.4 and 0.7
in these tissues (Fig. 2C).
Similar RFLP analyses were performed on a collection of
cDNAs extracted from human prostate tumors. As shown in
Fig. 2D, the I117/T117 ratio varied greatly among tumors (from
0.1 to 0.9). Interestingly, the I117/T117 ratio averaged 0.42 in
15 prostate tumors that were analyzed, while the pool of
cDNAs from 32 healthy prostate samples gave an average
735D. Hodzic et al. / Genomics 88 (2006) 731–736I117/T117 ratio of only 0.12 (Fig. 2C). Furthermore, the
transcription of M157 paralogues (genes A–D), undetectable
in normal prostate tissues, was readily detected in 3 prostate
tumors. Two of these tumors (T23 and T29) displayed a
M157/I157 greater than 1.
Discussion
Here, we demonstrate that TBC1D3 represents a family of
molecules encoded by up to eight paralogues clustered in the
q12 region of chromosome 17. The alignment of the predicted
translation products of these paralogues revealed six missense
changes. Given that two pairs of paralogues (C/D and E/F)
encode the same combination of missense changes, TBC1D3
potentially exists as six protein variants. ESTs corresponding to
all TBC1D3 transcription units support the notion that a
minimum of six paralogues are expressed.
Our results indicate that a single member of the TBC1D3
family (paralogue H encoding the T117 variant) is expressed in
the heart. Most tissues expressed at least two isoforms (I117 and
T117) that could correspond to the transcription of up to four
paralogues (E–H) located at 33,300K–33,700K. The most
complex transcription pattern was observed in pancreas,
thymus, and testis, where at least three isoforms (I117, T117,
and M157), which could be transcribed from up to all eight
TBC1D3 paralogues, exist.
Interestingly, 3 of 15 primary prostate tumors evaluated
expressed the M157 transcripts originating from TBC1D3
paralogues A–D. These transcripts (paralogues A–D) were
not detected in a mixed pool of 32 healthy prostate tissues
cDNA, suggesting selective transcriptional activation of para-
logues A–D in some prostate tumors.
The biological significance of variant forms of TBC1D3 is
still unknown. Although TBC1D3 is present only in hominoids,
the TBC domain is conserved across a broad range of species.
The variation within the TBC domain seen in the 17q
paralogues (A–H) is also seen in the TBC domain of other
species, with one notable exception: the T117 isoform that was
found only in the human genome. Whether the change from a
nonpolar (isoleucine) to a polar residue (threonine) and the
acquisition of a phosphorylatable residue can affect the
physiological function of that isoform remains to be determined.
The discovery of a biological function specific for the T117
isoform would be especially relevant in the heart, where it is the
sole transcribed paralogue.
As mentioned earlier, we found that 40 cycles of amplifica-
tion were necessary to detect a TBC1D3 PCR amplification
product on SYBR green-stained agarose gels while, under the
same conditions, GAPDHwas already very abundantly detected
after 25 amplification cycles. This result is in agreement with Pei
et al. [5], who found very low levels of TBC1D3 transcript by
Northern blot and semiquantitative RT-PCR. Furthermore, we
have had difficulty detecting the endogenous TBC1D3 protein in
various human cell lines and human tissues examined with
several anti-TBC1D3 antibodies. Interestingly, the TRE2
transcript, encoded by the chimeric fusion of TBC1D3 and
USP32, also displays low expression levels in most humantissues but testis [7] and is also undetectable using specific
antibodies in several cell lines [12,13].
How does TBC1D3 act as an oncogene? One hypothesis is
that following TBC1D3 overexpression, vesicular trafficking
would alter signaling events. Indeed, TBC1D3 possesses a TBC
domain and a GAP activity of TBC1D3 toward RAB5A has
been reported [5]. However, the latter is weak compared to
RNTRE (data not shown), a well-known RAB5A GAP [9].
Furthermore, and similar to TRE2, which does not display any
GAP activity [14], the TBC domain of TBC1D3 does not
display the evolutionarily conserved amino acid residue motif
(“arginine finger”) that is found in RNTRE and conserved
among active GAP proteins from yeasts to mammals [15].
A second hypothesis is that overexpression of TBC1D3 may
be oncogenic because it interferes with the deubiquitination
activity of TRE2. Indeed, the oncogenicity of TRE2 is linked to
the overexpression of a specific transcript encoding the N-
terminal region of the protein [6], which has been proposed to
act in a dominant negative manner on the deubiquitination
activity of the full-length TRE2 protein [16]. A similar
oncogenic mechanism can be hypothesized for TBC1D3,
whose amino acid sequence displays more that 80% identity
with the oncogenic variant of TRE2.
In conclusion, highly related TBC1D3 variants are tran-
scribed from up to eight paralogues clustered on chromosome
17q12, resulting in six variant TBC1D3 proteins. Specific
patterns of expression of these paralogues were observed in
different normal human tissues and altered in several prostate
tumors in comparison to healthy prostate tissue. Further analysis
of the TBC1D3 gene expression pattern in other tumors as well
as functional characterization of the variants will be necessary
to understand the oncogenic mechanism of TBC1D3.
Materials and methods
Construction of the TBC1D3 library
Total RNA was extracted from placenta with Trizol (Invitrogen). One
microgram of total RNA was used for reverse-transcription with oligo(dT)
primers and SuperScript II reverse transcriptase following the recommendations
of the manufacturer (Invitrogen). The PCR was performed with Pfu Turbo
(Stratagene) using forward primer 5′-CCGGAATTCCGGATGGACGTGGTA-
GAGGTCGC-3′ and reverse primer 5′-ATAAGAATGCGGCCGCTAAAC-
TATCTAGAAGCCTGGAGGGAACT-3′ to obtain the full-length TBC1D3
cDNA. The latter was cloned in pCR2.1-TOPO and transformed in TOP 10
bacteria (Invitrogen). The whole transformation (1 ml) was further grown in
50 ml of LB medium and plasmid DNAwas extracted from the bacteria (Wizard
Plus Midipreps; Promega) to obtain the TBC1D3 library.
RFLP analyses
The TBC1D3 library was digested with ApaI (New England Biolabs) and
the expected 1075-bp fragment was purified from a preparative agarose gel (Gel
Extraction Kit; Qiagen) and digested with NdeI (New England Biolabs). The
ApaI fragment was extensively sequenced to confirm the RFLP findings and
to interrogate other missense changes that did not produce RFLPs. To examine
the DdeI polymorphism, a 420-bp fragment corresponding to the N-terminal
region of TBC1D3 was PCR-amplified from the TBC1D3 library with Pf1 (5′-
CCGGAATTCCGGATGGACGTGGTAGAGGTCGC-3′) and Pr420 (5′-
CTCAGATGACCTCTTGCCCTT-3′) and digested with DdeI. All enzymatic
digestions were carried out at 37°C for 3 h.
736 D. Hodzic et al. / Genomics 88 (2006) 731–736To examine the NdeI and DdeI RFLPs in human tissue cDNAs (Human
MTC Panels I and II; BD Biosciences), a 340-bp fragment containing both NdeI
and DdeI polymorphic sites was PCR-amplified with Pfu Turbo using 5 μl
(5 ng) of each aliquot of cDNA in combination with primers Pf200 (3′-
AATTCGGCGGGAGATCAGCCGAAA-5′) and Pr540 (5′-ATACTCCTCA-
TATGCCAGGAGGAT-3′) in a final 25-μl reaction volume. Eight microliters of
that PCR was used for restriction digests. The same procedure was carried out
with prostate tumor cDNAs (kindly provided by Dr. M.A. Watson, Tissue
Procurement Core Facility, Washington University School of Medicine, St.
Louis, MO, USA). Restriction digestion products were run on a 4% SeaPlaque
GTG agarose gel (BMA, Rockland, ME, USA) and stained with SYBR green I
(Molecular Probes, Eugene, OR, USA). Gels were imaged with a digital camera
(ChemImager Ready; Alpha Innotech Corp., San Leandro, CA, USA) and
restriction fragments quantified (FluorChem 8900) to estimate the I117/T117 and
M157/I157 ratio.Acknowledgments
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